Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations [Yahoo! Finance]
Navidea Biopharmaceuticals, Inc. (NAVB)
NASDAQ:AMEX Investor Relations:
ir.navidea.com
Company Research
Source: Yahoo! Finance
The company maintains strategic focus on its Fix, Fund, Propel approach. COLUMBUS, Ohio, January 27, 2024 BUSINESS WIRE )--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act (the "Deregistration"). The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and
Show less
Read more
Impact Snapshot
Event Time:
NAVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAVB alerts
High impacting Navidea Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NAVB
News
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat